OTLK Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
8.7K
-93.2%
127.4K
+110.6%
-1207833
1.5M
Cost of Revenue
17.0K
-88.6%
149.3K
+404.0%
29.6K
0
-100.0%
439.8K
Gross Profit
-8265
+62.2%
-21888
+98.2%
-1237459
1.1M
Operating Expenses
10.8M
-22.9%
14.0M
+14.4%
12.2M
16.8M
R&D
3.3M
-27.8%
4.5M
+23.8%
3.6M
7.1M
SG&A
7.6M
-20.6%
9.5M
+10.4%
8.6M
9.7M
Operating Income
-10810209
+22.9%
-14026987
-4.0%
-13483952
-15748680
EBITDA
-10796418
+22.9%
-13996570
-4.0%
-13453878
-45342.9%
29.7K
+100.2%
-15719268
Net Income
-20319272
-356.3%
-4453081
+80.7%
-23058135
-20152502
EPS (Basic)
$-0.15
-200.0%
$-0.05
+86.8%
$-0.38
$-0.55
EPS (Diluted)
$-0.15
-200.0%
$-0.05
+86.8%
$-0.38
$-0.55
Shares (Diluted)
136.7M
+67.1%
81.8M
+35.9%
60.2M
+27.8%
47.1M
+27.5%
37.0M
Outlook Therapeutics (OTLK) — Financials